Short answer
MEDIFAST INC (MED) filed its Q3 2025 10-Q quarterly report on Nov 3, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $89M (down 36.2% year over year) with net income of −$2M.
Q3 2025 key financials · XBRL
- Revenue
- $89M
- −36.2% YoY · −15.3% QoQ
- Net income
- −$2M
- −300.6% YoY · −191.2% QoQ
- Operating margin
- -4.6%
- Gross margin
- 69.5%
- EPS (diluted)
- −$0.20
- −281.8% YoY · −190.9% QoQ
Source: XBRL data from the MEDIFAST INC (MED) Q3 2025 10-Q on SEC EDGAR. USD.
MEDIFAST INC Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $89.4M, down 36.2% YoY from $140.2M, driven by fewer active earning coaches
- Gross margin 69.5% vs 75.4% YoY; operating margin (4.6%) vs 1.5%
- Active earning coaches 19,500, down 35.0% from 30,000; revenue per coach $4,585 vs $4,672
- Client acquisition pressured by rapid GLP-1 adoption and broader operating-environment challenges
- Next-generation metabolic-health product line expected to launch next year; inflation and tariff uncertainty remain headwinds
Risk Factors
- No risk-factors section provided; changes from the most recent 10-K cannot be assessed
- Repurchase-plan risk: 1,323,568 shares remain eligible, with timing and pricing dependent on market conditions
- Equity-plan dilution risk: 77 shares surrendered for employee and director tax-withholding obligations at $13.71 per share
- Regulatory compliance: no director or officer adopted or terminated Rule 10b5-1 or non-Rule 10b5-1 arrangements during the quarter
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other MEDIFAST INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.